InspireMD reports 30-day clinical trial results for CGuard Prime 80 cm implant in TCAR

Filed June 11, 2026 · Period ending June 11, 2026 · ~1 min read

Key Changes

• high

  Company disclosed 30-day results from CGUARDIANS II trial evaluating CGuard Prime 80 cm implant for transcarotid artery revascularization (TCAR) procedures, a minimally invasive stroke prevention treatment.

  Item 7.01 verify on EDGAR →
• high

  Results released under Regulation FD, ensuring all investors receive clinical data simultaneously. Full trial outcomes and safety data are in the attached press release.

  8-K: Reg FD Disclosure verify on EDGAR →